Codexis FY 2025 Results: Revenue Rebounds As Profitability Swings Positive In Q4

Codexis (CDXS) closed FY 2025 with a sharp Q4 reset, reporting US$38.9 million in revenue and basic EPS of US$0.11, alongside net income of US$9.6 million, against a trailing twelve month loss of US$44.0 million and a TTM basic EPS loss of US$0.50. The company has seen quarterly revenue move from US$21.5 million in Q4 2024 to US$7.5 million in Q1 2025, US$15.3 million in Q2 2025, US$8.6 million in Q3 2025, and then up to US$38.9 million in Q4 2025. Quarterly basic EPS shifted from a loss of US$0.13 in Q4 2024 through losses of US$0.25, US$0.16, and US$0.22 in the first three quarters of 2025 before the Q4 profit. For investors, the jump to positive EPS in the latest quarter against ongoing TTM losses puts the focus squarely on whether this margin improvement can be sustained.

See our full analysis for Codexis.

With the headline numbers on the table, the next step is to see how this mix of revenue recovery and margin improvement lines up with the main Codexis narratives that have been driving expectations over the past year.

TTM Loss Of US$44.0 Million Keeps Profit Story In The Red

• Across the last twelve months, Codexis booked US$70.4 million in revenue but recorded a net loss of US$44.0 million and a basic EPS loss of US$0.50, so the Q4 profit sits against a still loss-making year.
• Consensus narrative highlights faster revenue growth of 23.6% per year and projected earnings growth around 60.8% a year. However, the five-year pattern of losses increasing about 28.4% a year keeps the focus on whether higher-margin ECO and biocatalysis work can genuinely shift that long-running loss profile.
  • Analysts' consensus view points to a revenue growth assumption of 29.3% a year and an eventual margin move toward industry levels. This contrasts with the current loss of US$43.97 million over the latest twelve months.
  • That gap between a loss-making base today and expectations of improved margins is why the recent Q4 profit is being watched closely rather than treated as a finished turnaround.

23.6% Revenue Growth Meets Short Cash Runway

• Trailing twelve-month revenue growth of 23.6% per year is running ahead of the cited 10.4% growth for the broader US market, while the company is reported to have less than one year of cash runway, so growth is paired with funding pressure.
• Bulls argue that strong ECO Synthesis demand and expanding enzyme partnerships can support higher long-term margins and recurring revenue. However, the short cash runway and historical loss trend mean the bullish case leans heavily on that growth turning into cash generation quickly enough to support operations.
  • The bullish narrative leans on assumptions such as revenue growing 37.7% a year and profit margins moving from roughly 114% loss to 14.2% profit by around 2028, compared with the current twelve-month net loss of US$43.97 million.
  • With the share price at US$1.71 versus an analyst consensus target of about US$6.58, the gap between current results and bullish long-term expectations is wide and depends on ECO and RNA opportunities scaling in line with those growth assumptions.

Have a closer look at why some investors think Q4 is the start of a much bigger earnings shift for Codexis, and how they frame the upside versus the risks in RNA and ECO Synthesis opportunities. 🐂 Codexis Bull Case

US$1.71 Share Price, Ongoing Losses And Valuation Debate

• With the stock at US$1.71 and a P/S ratio of 2.2x compared with peers at 6.8x and the US Life Sciences industry at 2.8x, Codexis screens as cheaper on sales while still carrying a twelve-month loss of US$44.0 million and above-market share price volatility in the last three months.
• Bears argue that reliance on early-stage ECO Synthesis projects, capital-intensive GMP build-out and a history of widening losses could require more funding and keep profitability out of reach longer. This would test any valuation based on higher future margins and revenue growth.
  • The cautious narrative still assumes revenue growth of 27.7% a year but points out that analysts are not forecasting profitability within the next three years, in line with the current basic EPS loss of US$0.50 over the last twelve months.
  • Given the limited cash runway and a five-year pattern of losses rising about 28.4% a year, critics focus on the risk that additional capital could be needed if ECO contracts and late-stage programs do not scale quickly enough.

If you are weighing whether the recent Q4 profit meaningfully shifts the risk side of the story, it is worth seeing how more cautious investors interpret the cash runway, GMP spend and early-stage ECO pipeline against the current share price. 🐻 Codexis Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Codexis on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With such mixed sentiment around Codexis right now, it makes sense to check the numbers yourself and decide quickly where you stand, starting with 2 key rewards and 2 important warning signs.

Explore Alternatives

Codexis still carries a twelve month net loss of US$44.0 million, a basic EPS loss of US$0.50 and a short cash runway despite the Q4 profit.

If that mix of ongoing losses and funding pressure feels uncomfortable, you can quickly refocus on companies with steadier profiles by scanning 69 resilient stocks with low risk scores right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.